Avatar
Movespace3

0 Following 0 Followers
1
N ( ) Homeless, self-described, n ( ) Receiving public assistance or social security disability, n ( ) Employed, n ( ) CES-D short-form scorea, median (IQR) 44 (85) 8 (15) 47 (42?2) 29 (56) 20 (39) 41 (79) 8 (15) 11 (5?6) 44 (80) 11 (20) 47 (41?1) 27 (49) 12 (23) 50 (91) 8 (15) 11 (6?5) 19 (37) 17 (33) 4 (8) 7 (13) 5 (10) 27 (52) 20 (36) 18 (33) 4 (7) 7 (13) 6 (11) 24 (44)Substance abuse relatedDu
1
N ( ) Homeless, self-described, n ( ) Receiving public assistance or social security disability, n ( ) Employed, n ( ) CES-D short-form scorea, median (IQR) 44 (85) 8 (15) 47 (42?2) 29 (56) 20 (39) 41 (79) 8 (15) 11 (5?6) 44 (80) 11 (20) 47 (41?1) 27 (49) 12 (23) 50 (91) 8 (15) 11 (6?5) 19 (37) 17 (33) 4 (8) 7 (13) 5 (10) 27 (52) 20 (36) 18 (33) 4 (7) 7 (13) 6 (11) 24 (44)Substance abuse relatedDu
1
D a commercial statistical software package to generate random treatment assignments to DAART and SAT in a 1:1 ratio,Directly Administered Therapy for HIVTable 1. Baseline characteristics of HIV-infected participants in a randomized trial comparing directly administered antiretroviral therapy with self-administered therapy in opioid treatment programs, Baltimore, Maryland, 2006?010.CharacteristicS
1
G directly administered antiretroviral therapy with self-administered therapy in opioid treatment programs, Baltimore, Maryland, 2006?010.Differencea (95 CI)SAT (N = 52) Virologic and immunologic outcomes Average proportion with HIV RNA ,50 copies/mL during interventionb Average proportion with HIV RNA ,400 copies/mL during intervention Average change from baseline in log10 HIV RNA during interve
1
Use of the monitors and asked them to return at 1 week, 4 weeks, and 8 weeks to download data from the monitors. Research assistants did not review recorded adherence data with participants. The protocolEthics StatementEach participant provided written informed consent and the study protocol was approved by the Johns Hopkins Medicine Institutional Review Board (IRB), the University of Maryland IRB
1
St injected .6 months ago Injected within last 6 months Urine drug test, positive results, n ( ) Opiate Cocaine AUDITb10 (2?4) 48 (92) 95 (70?20) 4 (8) 19 (12?6) 43 (83)11 (2?1) 51 (93) 80 (70?10) 4 (7) 21 (10?0) 44 (80)8 (15) 18 (35) 26 (50)2 (4) 31 (56) 22 (40)9 (17) 18 (35) 10 (19)12 (22) 24 (44) 10 (18)score 8, n ( )HIV relatedEmergency department visit or hospitalization in prior 3 months, n
1
Use of the monitors and asked them to return at 1 week, 4 weeks, and 8 weeks to download data from the monitors. Research assistants did not review recorded adherence data with participants. The protocolEthics StatementEach participant provided written informed consent and the study protocol was approved by the Johns Hopkins Medicine Institutional Review Board (IRB), the University of Maryland IRB
1
Istically significant period effect was found (P values i0.52). The primary statistical analysis gave an estimate of the reduction in saquinavir exposure when coadministered with rifabutin, as measured by AUC(0,8 h) and Cmax(0,8 h) of 47 (95 CI 30, 60 ) and 39 (95 CI 11, 59 ), respectively. Figure 1 illustrates the plasma concentrationtime profiles for saquinavir when administered alone (Treat